2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Por:
Farge, D, Frere, C, Connors, JM, Ay, C, Khorana, AA, Muno, ZA, Brenner, B, Kakkar, A, Rafii, H, Solymoss, S, Brilhante, D, Monreal, M, Bounameaux, H, Pabinger, I and Douketis, J
Publicada:
1 oct 2019
Ahead of Print:
3 sep 2019
Categoría:
Oncology
Resumen:
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis. The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods, with the support of the French National Cancer Institute. These guidelines were reviewed by an expanded international advisory committee and endorsed by the International Society on Thrombosis and Haemostasis. Results from head-to-head clinical trials that compared direct oral anticoagulant with low-molecular-weight heparin are also summarised, along with new evidence for the treatment and prophylaxis of VTE in patients with cancer.
Filiaciones:
Farge, D:
Univ Paris, Ctr Reference Rare Syst Autoimmune Dis FAI2R, Internal Med UF04, Autoimmune & Vasc Dis Unit, Paris, France
McGill Univ, Dept Med, Montreal, PQ H4A 3J1, Canada
Frere, C:
Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Haematol,UMRS 1166, Paris, France
Connors, JM:
Harvard Med Sch, Brigham & Womens Hosp, Hematol Div, Boston, MA 02115 USA
Ay, C:
Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna, Austria
Khorana, AA:
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
Cleveland Clin, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
Muno, ZA:
Univ Complutense, Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
Brenner, B:
Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, Haifa, Israel
Kakkar, A:
Thrombosis Res Inst, London, England
UCL, London, England
Rafii, H:
Univ Paris, St Louis Hosp, AP HP, Eurocord, Paris, France
Solymoss, S:
McGill Univ, Dept Med, Montreal, PQ H4A 3J1, Canada
Brilhante, D:
Lisbon Ctr, Francisco Gentil Portuguese Inst Oncol, Lisbon, Portugal
:
Univ Catolica Murcia, Hosp Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain
Bounameaux, H:
Univ Hosp Geneva, Fac Med, Div Angiol & Hemostasis, Geneva, Switzerland
Pabinger, I:
Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna, Austria
Douketis, J:
McMaster Univ, Dept Med, Hamilton, ON, Canada
Green Published
|